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Abstract
Background: Statins are first-line pharmacotherapeutic agents for hypercholesterolemia treatment in humans.
However the effects of statins on atherosclerosis in mouse models are very paradoxical. In this work, we wanted to
evaluate the effects of simvastatin on serum cholesterol, atherogenesis, and the expression of several factors
playing important roles in reverse cholesterol transport (RCT) in apoE-/- mice fed a high-fat diet.
Results: The atherosclerotic lesion formation displayed by oil red O staining positive area was reduced significantly
by 35% or 47% in either aortic root section or aortic arch en face in simvastatin administrated apoE-/- mice
compared to the control. Plasma analysis by enzymatic method or ELISA showed that high-density lipoprotein-
cholesterol (HDL-C) and apolipoprotein A-I (apoA-I) contents were remarkably increased by treatment with
simvastatin. And plasma lecithin-cholesterol acyltransferase (LCAT) activity was markedly increased by simvastatin
treatment. Real-time PCR detection disclosed that the expression of several transporters involved in reverse
cholesterol transport, including macrophage scavenger receptor class B type I, hepatic ATP-binding cassette (ABC)
transporters ABCG5, and ABCB4 were induced by simvastatin treatment, the expression of hepatic ABCA1 and
apoA-I, which play roles in the maturation of HDL-C, were also elevated in simvastatin treated groups.
Conclusions: We demonstrated the anti-atherogenesis effects of simvastatin in apoE-/- mice fed a high-fat diet.
We confirmed here for the first time simvastatin increased the expression of hepatic ABCB4 and ABCG5, which
involved in secretion of cholesterol and bile acids into the bile, besides upregulated ABCA1 and apoA-I. The
elevated HDL-C level, increased LCAT activity and the stimulation of several transporters involved in RCT may all
contribute to the anti-atherosclerotic effect of simvastatin.
Background
Statins are class of drug used to lower cholesterol levels by
inhibiting the enzyme 3-hydroxy-3-methyl-glutaryl-CoA
reductase (HMGCR), which plays a central role in the pro-
duction of cholesterol in the liver. Increased cholesterol
levels have been associated with cardiovascular diseases
(CVD), and statins are therefore first-line pharmacothera-
peutic agents for the treatment of these diseases in
humans. Recently a great line of animal species have been
used to study the pathogenesis and potential treatment of
the lesions of atherosclerosis. However until now the
effects of statins in animal models of atherosclerosis are
not very consistent. The apoE-knockout (apoE-/-) mouse
is a well-established genetic mouse model of atherogenic
hypercholesterolemia, in which mice spontaneously
develop atherosclerosis with similar features to those
observed in human type III familial hyperlipoproteinemia.
Florian Bea et al. has reported simvastatin increased serum
cholesterol and atherosclerotic lesion size in apoE-/- mice
fed a chow diet although the plaque stability was increased
[1]. In this work, we wanted to evaluate the effects of sim-
vastatin on serum cholesterol and atherogenesis in
apoE-/- mice fed a high-fat diet.
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crucial for preventing atherogenesis and hence the
development of most cardiovascular diseases. This anti-
atherogenic mechanism involves export of cholesterol
from lipid-laden macrophages in the artery wall back to
the liver for eventual excretion. The process of RCT can
be divided into three stages: 1) the efflux of cellular cho-
lesterol to high-density lipoprotein (HDL) from periph-
eral cells. Macrophage ATP-binding cassette transporter
(ABC) A1, ABCG1 and scavenger receptor class B type I
(SR-BI) all play important roles in the first stage. 2) the
transport of HDL-cholesterol (HDL-C) in blood to the
liver. The cholesterol in HDL is converted to cholesteryl
esters (CE) by the enzyme lecithin-cholesterol acyltrans-
ferase (LCAT) and carried as CE in the core of the HDL
particle to the liver. 3) the delivery of cholesterol esters
to hepatocytes from HDL [2]. After uptaking of HDL-
accociated cholesterol into hepatocytes by heptic SR-BI,
secretion of cholesterol, bile acids, and phospholipid
into the bile is regulated by the respective transporters
ABCG5, ABCG8, ABCB4 and ABCB11. Simvastatin has
been reported to improve RCT in type 2 diabetic
patients with hyperlipidemia [3]. However, the effects of
simvastatin on the important factors playing roles in
RCT has not been elucidated. In the present study, we
hypothesized that simvastatin might promote the
expression of several factors involved in RCT. Therefore,
we investigated the effects of simvastatin on the expres-
sion of several transporters, including macrophage
ABCA1, ABCG1 and SR-BI, hepatic SR-BI, ABCG5,
ABCG8, ABCB4 and ABCB11. Besides transporters, we
also detected the effects of simvastatin on plasma LCAT
activities and apoA-I concentrations, which also play
roles in RCT in apoE-/- mice.
Methods
Animals and Experimental Design
21 male apoE-/- mice were purchased from laboratory
animal center of Academy of Military Medical Sciences
(Beijing). All experiments were approved by the labora-
tory animals’ ethical committee of Taishan Medical
University and followed national guidelines for the care
and use of animals. At 5 weeks of age, the 21 apoE-/-
mice were randomly divided into 2 groups, the model
group (n = 11, vehicle treated group) and the simvasta-
tin (5 mg/kg/d) treated group (n = 10). All groups were
fed an atherogenic high-fat diet (15.8% fat and 1.25%
cholesterol) supplemented with vehicle or simvastatin
for 6 weeks. Vehicle or simvastatin were administered
intragastrically once daily.
Plasma analyses
After 6 weeks of treatment, blood was collected from
the retro-orbital sinus of the mice without dietary
exposure for 12 h. Concentrations of plasma total cho-
lesterol (TC), HDL-C, and triglycerides (TG) were deter-
mined by enzymatic methods (BioSino). Non-HDL-C
was calculated as TC minus HDL-C. Plasma concentra-
tions of apolipoprotein A-I (apoA-I) was determined by
ELISA kit (BlueGene). Endogenous lecithin-cholesterol
acyltransferase (LCAT) activity was measured as the uti-
lization rate of free cholesterol (FC) in native plasma
according to the method by Ly et al. [4]. The FC con-
tent was measured colorimetrically by using a kit (Biovi-
sion) in pentuplicate by a microplate reader (Tecan) at
zero time and after 1 hr at 37°C. LCAT activity was
expressed as nanomoles FC consumed per hr per ml
plasma.
Lesion Analysis
The proximal aorta attached to the heart was used to
prepare cross-sections. Cryosections (8 μm) were cut
f r o mt h es i t ew h e r et h ea o r t av a l v ec u p sa p p e a ra tt h e
aorta root, collected and stained with oil red O and brilli-
ant green. The volume of stained lipids (μm
2) was calcu-
lated from five sections for an animal. For determination
of atherosclerotic plaque area in aortic arch, the aortic
arch were dissected and stained en face with oil red O.
Quantitative analysis of plaque area was performed by
2 blinded observers using Image-Pro Plus software 4.5
(Media Cybernetics).
Western Blots
Tissues or cells were harvested and protein extracts pre-
pared as previously described [5]. They were then sub-
jected to western blot analyses using anti-ABCA1,
ABCG1, SR-BI, apoA-I, and b-actin antibodies (Santa
Cruz). The proteins were visualized and quantified using
a chemiluminescence method (Pierce) and Quantity
One (Bio-Rad) software program.
Isolation of Peritoneal Macrophages
Three days after intraperitoneal thioglycollate injection,
peritoneal macrophages were harvested from six weeks
simvastatin or vehicle treated apoE-/- mice. Following
collection, peritoneal macrophages were immediately
frozen at -80°C until RNA or protein extraction.
Quantitative Real-Time PCR
Total cellular RNA was isolated by TRIZOL Reagent
(Invitrogen). cDNA synthesis was performed using
MuLV Reverse Transcriptase (Applied Biosystems).
Real-time PCR was performed using a SYBR-green PCR
master mix kit (TianGen Biotech). The primers used for
real-time PCR were listed in Table 1. The data was ana-
lyzed by using Rotor-gene Q software ver. 1.7 (Qiagen).
Relative mRNA levels were calculated by the method
of 2
-DDCt.
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Statistical analysis was performed by one-way analysis of
variance (ANOVA) test with the GraphPad Prism pro-
gramme ver.4.0. Results are expressed as means ± SD.
P values less than 0.05 were considered significant.
Results
Simvastatin decreases atherosclerotic lesion formation in
apoE-/- mice fed a high-fat diet
As shown in Figure 1, administration of simvastatin with
5.0 mg/kg significantly inhibited the formation of athero-
sclerotic lesions in cross-sections of the aortic valve area
by 35% compared with model group (Figure A and B).
En-face oil-red O staining of the aortic arch also revealed
a significant 47% reduction of atherosclerotic plaque
formation in simvastatin-treated animals (Figure C). The
inhibitory effect of simvastatin with doses less than
5.0 mg/kg on the formation of atherosclerotic lesions was
not so obvious as that of 5.0 mg/kg of the medication
(data not shown).
Effect of simvastatin on plasma lipoprotein profiles and
plasma LCAT activities
As shown in Table 2, plasma TC, TG, and non-HDL-C
levels after 6 weeks of treatement were not affected by
simvastatin. Plasma HDL-C levels, however in mice fed
5.0 mg/kg of simvastatin were significantly higher
(19.4% upregulation) than that in model group. In addi-
tion, administration of simvastatin significantly increased
plasma levels of apoA-I (Table 2) and LCAT activities
(Figure 2).
Effect of simvastatin on the expression of hepatic genes
involved in cholesterol metabolism
As shown in Figure 3 A, simvastatin treatment increased
the mRNA levels of hepatic apoA-I and ABCA1 up to
approximate 1.55-fold (P < 0.05) and 2.5-fold (P < 0.05),
respectively. The mRNA levels of ABCG5 and ABCB4
were also elevated by simvastatin treatment up to
approximate 1.7-fold (P < 0.05) and 1.9-fold (P < 0.05),
respectively. In addition, the mRNA levels of ABCG1,
apoA-II, SR-BI, LCAT, ABCG8, ABCB11 and LXRa
were not affected by simvastatin. This difference in
hepatic LCAT mRNA levels was not reflected in plasma
LCAT activity, suggesting that post-transcriptional regu-
lation plays an important role in LCAT function.
Furthermore, as shown in Figure 3 B and C, the protein
levels of ABCA1 and apoA-I were elevated and the
levels of ABCG1 and SR-BI were not affected by simvas-
tatin treatment.
Effect of simvastatin on the expression of transporter
genes involved in cholesterol efflux in peritoneal
macrophages
The effect of simvastatin on the expression of macro-
phage ABCA1, ABCG1 and SR-BI, which play important
roles in cholesterol efflux from peripheral tissues was
determined. Real-time PCR and western blot analysis
showed that SR-BI expression was significantly increased
and the expression of ABCA1 and ABCG1 was not
affected by simvastatin treatment (Figure 4).
Discussion
In the present study, we confirmed simvastatin-treatment
not only promoted plasma HDL-C, apoA-I levels, LCAT
activities and macrophage SR-BI expression, but also
increased the expression of hepatic ABCB4 and ABCG5
besides upregulated hepatic ABCA1 and apoA-I, and
reduce atherosclerotic lesion size in apoE-/- mice fed a
high-fat diet. It is well-known that statins are first-line
pharmacotherapeutic agents for hypercholesterolemia
treatment in humans. However the effects of statins on
atherosclerosis and lipid levels in mouse models are very
paradoxical. Nachtigal P et al. have shown atorvastatin
could increase plasma HDL-C and decrease TC levels in
apoE/LDL receptor-double-knockout mice fed an athero-
sclerotic diet [6]. Previous studies [1,7,8] in which the
simvastatin administered to the apoE-deficient mice
showed that the plasma cholesterol levels of the treated
animals fed a chow diet weres i g n i f i c a n t l ye l e v a t e d
Table 1 Primers used for real-time PCR analysis
Gene Primer Sequence (5`-3`)
ABCA1 Sense CGTTTCCGGGAAGTGTCCTA
Anti-sense GCTAGAGATGACAAGGAGGATGGA
ABCG1 Sense GGGAAGTTGATAAAGGATGT
Anti-sense GATTCGGGCTATGTATGG
SR-BI Sense ATCTGGTGGACAAATGGAA
Anti-sense GAAGCGATACGTGGGAAT
apoA-I Sense GGCACGTATGGCAGCAAGAT
Anti-sense CCCAGAAGTCCCGAGTCAAT
apoA-II Sense CCAAGGCATACTTTGAGAAGACAC
Anti-sense GGAGAAAACAGGCAGAAGGTAGG
LCAT Sense CCCACCAGCAGGATGAATACTAC
Anti-sense AGGCTATGCCCAATGAGGAA
ABCG5 Sense AGCGTCAGCAACCGTGTC
Anti-sense AGCAGCGTGGTCTTCCCT
ABCG8 Sense TTAAGCCACTCCCAATACA
Anti-sense GTTGCTCCAAGAATAAATGA
ABCB11 Sense CAAATAAGGTTGTGGGTAA
Anti-sense AGGACTGACAGCGAGAAT
ABCB4 Sense CCCCACAGAGGGTAAGAT
Anti-sense CCAACCAGGGTGTCAAAT
LXRa Sense TTTGAGCAGCGTCCATTC
Anti-sense GCAGTCAGTGAGCCTTCG
GAPDH Sense TGACGTGCCGCCTGGAGAAA
Anti-sense AGTGTAGCCCAAGATGCCCTTCAG
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we confirmed simvastatin-treatment did not affect
plasma TC, TG and non-HDL-C levels, and significantly
decreased the atherosclerotic lesion size in apoE-/- mice
fed a high-fat diet. Our data was in agreement with Spar-
row et al. reported [9] that the administration of simvas-
tatin to apoE-deficient mice fed a high cholesterol diet
did not alter their plasma TC levels, Sparrow et al. also
found simvastatin decreases aortic cholesterol accumula-
tion in apoE-/- mice besides increased anti-inflammotory
effects, but the underlying mechanisms was not yet estab-
lished. In the present study we found that the simvastatin
administrated animals displayed atheroprotection may
involved the promoted reverse cholesterol transport by
up-regulated HDL-C and related genes expression,
including genes important for the formation of HDL-C
and genes important for secretion of cholesterol, bile
acids, and phospholipid into the bile. In addition, the
A
C
B
Figure 1 Simvastatin inhibits atherosclerotic lesion formation in apoE-/- mice fed a high-fat diet. A, Representative of Oil Red O-stained
aortic sections (10× magnification). B, Quantitation of lesion areas in Oil Red O-stained aortic sections by Image-Pro Plus software. C,
Quantification of atherosclerotic lesions in the en-face of the aortic arch. ** P < 0.01 versus model group.
Table 2 Effect of Simvastatin on plasma lipoprotein lipids
and apoA-I concentrations in apoE-/- mice
Model (apoE-/-) Simvastatin (5 mg/kg)
Animal number (n) 11 10
TC(mmol/L) 24.69 ± 5.34 22.07 ± 4.12
TG(mmol/L) 1.13 ± 0.37 1.24 ± 0.47
Non-HDL-C (mmol/L) 22.06 ± 4.87 18.93 ± 3.89
HDL-C (mmol/L) 2.63 ± 0.35 3.14 ± 0.34**
apo-AI(mg/dl) 4.24 ± 1.01 11.58 ± 2.03**
Values are the means ± SD. *compared with model, p < 0.05. **compared
with model, p < 0.01.
Figure 2 Effect of simvastatin on endogenous LCAT activity in
plasma. LCAT activity was measured as the utilization rate of FC in
native plasma. LCAT activity was expressed as nanomoles FC
consumed per hr per ml plasma. Data are expressed as means ± SD
(n = 10). * P < 0.05 versus model group.
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levels in apoE-/- mice might be attributable in part to the
possibility that the dyslipidemic profile of apoE-/- mice
fed a high-fat diet whose lipid profile is VLDL dominant,
is different from and more severe than that fed a chow
diet.
Plasma concentrations of HDL-C have strong inverse
correlations with risk of atherosclerotic cardiovascular
disease, independently of LDL-C levels [10]. ApoA-I is
the major protein component of HDL-C in plasma.
HDL-C and apoA-I exert anti-inflammatory, anti-
oxidant, anti-thrombotic, promoting RCT and vasodilat-
ing properties that could all potentially be involved in
their anti-atherogenic effects [11]. Here, we showed that
simvastatin-treatment increased plasma levels of HDL-C
and apoA-I. Our finding was in agreement with another
report, which has shown that 8 weeks of simvastatin-
treatment has a tendency to increase plasma HDL-C
levels in apoE-/- mice fed a high cholesterol diet [12].
Furthermore, apoA-I is mainly synthesized by liver and
hepatic ABCA1 exert anti-atherogenic effect via its con-
tribution to HDL-C formation by promoting lipid efflux
to apoA-I from hepatocytes [13]. Our previous study
have reported that rosuvastatin selectively stimulates
apolipoprotein A-I but not apolipoprotein A-II synthesis
in Hep G2 cells [14]. And in this study, our results
showed that the expressions of hepatic apoA-I and
ABCA1 were increased by simvastatin treatment in vivo,
these data gave us a clue that the elevated plasma HDL-
C level by simvastatin in this study might be closely
associated with the enhanced hepatic apoA-I and
ABCA1 expression stimulated by simvastatin.
One of the important anti-atherogenic effects of
HDL-C is to facilitate the efflux of cholesterol from per-
ipheral tissues and transport it back to the liver in a pro-
cess called RCT [15]. Recently, several key molecules
have been identified to play pivotal roles on RCT [16-18].
Macrophage ABCA1 facilitates cholesterol efflux from
cells to lipid-poor apoA-I, but not HDL [16,17], whereas
another two macrophage transporters, ABCG1, and
SR-BI are involved in the cholesterol efflux from macro-
phages mediated by HDL, but not apoA-I [18,19]. In our
study, we showed that simvastatin induced macrophage
SR-BI expression, which might lead to an increased
ABCG1
ABCA1
apoA-I
SR-BI
actin
Model Sim
A
B C
Figure 3 Effect of simvastatin on the expression of hepatic genes which play roles in cholesterol transport. A, Effect of simvastatin on
the mRNA expression of hepatic genes by real-time PCR. Expression levels of mRNA are indicated as fold differences compared with model
mice. B, Effect of simvastatin on the protein expression of hepatic genes by western blots. C, Densitometric quantitation of western blot data
(n = 5) by Quantity One software. * P < 0.05, ** P < 0.01 versus model group.
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Furthermore, LCAT which bound to HDLs in plasma
and play roles in RCT is an enzyme that converts free
cholesterol into cholesteryl ester and is critical for the
maturation and maintenance of normal HDL metabolism
in humans [20] and mice [21]. At present, the molecular
mechanism(s) that regulates plasma LCAT concentra-
tions is not well understood. LCAT activity depends in
part on the amount of the enzyme in plasma, and in part
on the substrate and cofactors available to the enzyme
[22], such as apoA-I, an activator of LCAT, and apoA-II,
an inhibitor of LCAT activity. Our results showed that
simvastatin-treatment did not influence the mRNA
expression of hepatic LCAT and apoA-II, but signifi-
cantly increased plasma LCAT activities, hepatic apoA-I
and plasma apoA-I concentrations. The discrepancy in
hepatic LCAT expression and plasma LCAT activity
might attributable to a post-transcriptional regulation of
LCAT or the upregulation of apoA-I, the activator of
LCAT, by simvastatin.
Besides macrophage transporters and plasma LCAT,
several hepatic transporters are also involved in the pro-
cess of RCT. The direct selective uptake of HDL-C by
the liver is mediated by SR-BI. However, in our study,
the expression of hepatic SR-BI was not altered in sim-
vastatin-treated mice. After uptaking of HDL-associated
cholesterol by SR-BI, secretion of cholesterol, bile acids,
and phospholipid into the bile is regulated by the
respective transporters ABCG5, ABCG8, ABCB4 and
ABCB11. Here, we showed for the first time that the
mRNA expression of ABCG5 and ABCB4 was upregu-
lated by simvastatin-treatment. These finding suggest
that simvastatin may exert anti-atherosclerotic effects by
stimulating the expression of transporters involved in
the process of RCT, including macrophage SR-BI, hepa-
tic ABCG5 and ABCB4. The mechanisms in which sim-
vastatin stimulated higher expressions of RCT related
genes in apoE-/- mice deserve further investigation.
Conclusions
In conclusion, we confirmed here for the first time sim-
vastatin increased the expression of hepatic ABCB4 and
ABCG5 besides upregulated ABCA1 and apoA-I in
apoE-/- mice. Our data show that in vivo administration
of simvastatin effectively attenuates atherosclerotic
lesion formation in apoE-/- mice fed a high-fat diet by
targeting several pathways involved in atherogenesis.
Elevated plasma apoA-I and HDL-C levels, increased
plasma LCAT activities, and the stimulation of reverse
cholesterol transporter gene expression may all contri-
bute to the beneficial effect of simvastatin. Our findings
provide a novel insight into the anti-atherosclerotic
effects of simvastatin besides its lipid-lowering effect.
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